SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brodsky RA. Biology and management of acquired severe aplastic anemia. Curr Opin Oncol 1998; 10: 9599.
  • 2
    Guinan EC. Clinical aspects of aplastic anemia. Hematol Oncol Clin North Am 1997; 11: 10251044.
  • 3
    Bacigalupo A, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, Van Lint MT, Tichelli A, McCann S, Marsh J, Ljungman P, Hows J, Marin P, Schrezenmeier H. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Acta Haematol 2000; 103: 1925.
  • 4
    Passweg JR, Socié G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Pasquini R, Rowlings PA, Speck B, Tichelli A, Zhang M-J, Horowitz MM, Bortin MM. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90: 858864.
  • 5
    Horowitz MH. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000; 37: 3042.
  • 6
    Storb R, Doney KC, Thomas ED, Appelbaum F, Buckner CD, Clift RA, Deeg HJ, Goodell BW, Hackman R, Hansen JA, Sanders J, Sullivan K, Weiden PL, Witherspoon RP. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236246.
  • 7
    Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Rozman C, Sobocinski KA, Speck B, Bortin MM. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269275.
  • 8
    Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, Bryant E, Clift R, Deeg HJ, Doney K, Flowers M, Hansen J, Martin P, Pepe M, Sale G, Sanders J, Singer J, Sullivan KM, Thomas ED, Witherspoon RP. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941949.
  • 9
    Deeg HJ, Self S, Storb R, Doney K, Appelbaum FR, Witherspoon RP, Sullivan KM, Sheehan K, Sanders J, Mickelson E, Thomas ED. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood 1986; 68: 13631368.
  • 10
    Niederwieser D, Pepe M, Storb R, Loughran TP Jr, Longton G. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br J Haematol 1988; 69: 2328.
  • 11
    Herrera-Garza JL, Jaime-Perez JC, Montemayor JL, Ibarra-Peart RE, Gomez-Almaguer D. High-dose peripheral blood stem cell transplant for multi-transfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant 1999; 24: 845848.
  • 12
    Schwinger W, Urban Ch, Lackner H, Kerbl R, Benesch M, Dornbusch HJ, Sovinz P, Schauenstein K, Schumm M, Handgretinger R. Unrelated peripheral blood stem cell transplantation with “megadoses” of purified CD34+ cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant 2000; 25: 513517.
  • 13
    Burt RK, Kuzel TM, Fishman M, Brush M, Villa M, Welles C, Rosen S, Traynor AE. Stem cell component therapy: supplement of unmanipulated marrow and CD34 enriched peripheral blood stem cells. Bone Marrow Transplant 1999; 23: 381386.
  • 14
    Atkinson K, Fay K, Nivision-Smith I, Downs K. Lenograstim administration to HLA-identical donor-recipient pairs to accelerate marrow recovery post-transplant. Bone Marrow Transplant 1997; 19: 1521.
  • 15
    Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM. Severe aplastic anemia; a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 6370.
  • 16
    Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, Rappeport JM. Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation 1985; 39: 671 673.
  • 17
    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295304.
  • 18
    Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon RP. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250259.
  • 19
    Rothberg PG, Gamis AS, Baker D. Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation. Clin Lab Med 1997; 17: 109118.
  • 20
    Champlin RE, Horowitz MM, van Bekkum DW Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C, Speck B, Bortin MM. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606613.
  • 21
    Wagner JL, Storb R. Allogeneic transplantation for aplastic anemia. In:ThomasED, BlumeKG, FormanSJ, editors. Hematopoietic cell transplantation. Oxford: Blackwell Scientific Publications; 1998. p 789806.
  • 22
    Cottler-Fox M, Cipolone K, Yu M, Berenson R, O'Shaughnessy J, Dunbar C. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T-cell depletion equivalent to elutriation. Exp Hematol 1995; 23: 320322.
  • 23
    Handgretinger R, Lang P, Schumm M, Taylor G, Neu S, Koscielnak E, Niethammer D, Klingebiel T. Isolation and transplantation of autologous peripheral CD34+ progenitor cell highly purified by magnetic-activated cell sorting. Bone Marrow Transplant 1998; 21: 987993.
  • 24
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 40634071.
  • 25
    Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B, Ramsay NK, Kersey JH, Filipovich A. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624 629.
  • 26
    Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, Flowers M, Sullivan KM, Witherspoon RP, Rowley SD, Hansen JA, Storb R, Appelbaum FR. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease. Blood 1997; 90: 47054709.
  • 27
    Deeg HJ, Leisenring W, Storb R, Nims J, Flowers MED, Witherspoon RP, Sanders J, Sullivan KM. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 36373645.
  • 28
    Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcome with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997; 126: 107115.
  • 29
    Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, Chauncey T, Clift RA, Deeg HJ, Doney KC, Flowers MED, Hansen JA, Martin PJ, Sullivan KM, Witherspoon RP. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89: 38903891.
  • 30
    Horstmann M, Stockschlader M, Kruger W, Hoffknecht M, Betker R, Kabisch H, Zander A. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 7781.
  • 31
    Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb HJ, Lerner KG, Schroeder ML, Thomas ED. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974; 112: 15081516.
  • 32
    McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, Marin C, Nissen C, van't Veer Kerthof E, Raghavachar A, Socie G, Frickhofen N, Locasciulli A, Schrezenmeier H. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233237.
  • 33
    Min C-K, Kim DW, Lee JW, Min WS, Kim CC. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 2000; 104: 185192.
  • 34
    Min C-K, Kim DW, Lee JW, Han CW, Min WS, Kim CC. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001; 86: 303310.
  • 35
    Rachamin N, Gan J, Segall H, Krauthgamer R, Marcus H, Berrebi A, Martelli M, Reisner Y. Tolerance induction by “megadose” hematopoietic transplants. Transplantation 1998; 65: 13861393.
  • 36
    Rutella S, Rumi C, Lucia MB, Sica S, Cauda R, Leone G. Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness. Exp Hematol 1998; 26: 10241033.
  • 37
    Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 15621568.